NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed)
ID: 356928Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356928

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-019.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the Sustainable Transformation of Institutional Research Rigor (STIRR) Program, a federal grant opportunity aimed at enhancing research rigor and transparency within academic and research institutions in the field of neuroscience. This initiative seeks to support innovative programs and strategies that promote high-quality research practices, emphasizing rigorous study design and transparent reporting to foster a culture of scientific integrity. The NIH plans to allocate approximately $3.5 million annually for up to five awards, with individual grants ranging from $150,000 to $800,000 over a three-year period. Interested applicants must submit their proposals by October 17, 2025, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-NS-25-019-Full-Announcement.html
    RFA-NS-25-019.html
    The Department of Health and Human Services, through the National Institute of Neurological Disorders and Stroke (NINDS), has announced the Sustainable Transformation of Institutional Research Rigor (STIRR) funding opportunity. This initiative seeks to enhance research rigor and transparency in neuroscience by supporting programs that cultivate high-quality research within academic and research institutions. Emphasis is placed on innovative strategies promoting rigorous study design and unbiased reporting practices. Eligible applicants include various educational and nonprofit organizations, with funding estimated at $3.5 million annually for up to five awards. Each award may range from $150,000 to $800,000 over three years. The application process requires adherence to specific guidelines and the submission of distinct, non-duplicative proposals. Successful programs must demonstrate a commitment to improving local research practices, ensuring sustainability beyond the funding period, and sharing outcomes with the broader scientific community. This NOFO aims to catalyze a culture change respecting rigor and transparency in neuroscience research, fostering replicable practices across institutions involved in the NINDS mission.
    Similar Opportunities
    Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)," aimed at enhancing research experiences for resident clinicians in training. This initiative seeks to recruit, retain, and foster the independence of clinician-investigators by providing them with essential research opportunities early in their careers, thereby supporting basic, clinical, and translational research efforts. Although applications are not currently being solicited, potential applicants are encouraged to prepare meaningful collaborations and projects in anticipation of the forthcoming Notice of Funding Opportunity (NOFO). Interested parties can reach out to Dr. David Schopfer at david.schopfer@nih.gov or by phone at 301-402-3833 for further information, with the estimated synopsis posting date on July 11, 2025, and a projected award date of May 1, 2026.
    Institutional Translational Research Training Program (T32 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Translational Research Training Program (T32), a federal grant aimed at equipping advanced predoctoral students, postdoctoral fellows, and fellowship-stage clinicians with the skills necessary to advance basic research toward clinical application, particularly in the field of neuroscience. This program emphasizes a cohesive educational approach that integrates training in experimental design, statistical analysis, and effective communication, while fostering interdisciplinary collaboration among scientists and clinicians and providing exposure to industry and regulatory processes. The grant will cover stipends, tuition, and training-related expenses for a duration of two years, with a focus on enhancing diversity in biomedical research. Interested applicants can find more information and apply by May 25, 2026, and should direct inquiries to grantsinfo@nih.gov.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Research Program Award (R35 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Program Award (R35 Clinical Trial Optional) aimed at providing long-term support and flexibility for Program Directors (PDs) and Principal Investigators (PIs) in the field of neurological research. This grant, which does not require cost sharing or matching, is designed to alleviate the administrative burdens associated with managing multiple grant applications, allowing researchers to focus on their scientific endeavors and mentorship roles. The funding, with an award ceiling of $750,000 and a floor of $350,000, is intended to foster innovative research that aligns with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants can reach out to Alisa Schaefer at nindsr35@ninds.nih.gov for further information, with the estimated synopsis posting date set for April 15, 2026, and a projected award date of March 1, 2027.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) funding opportunity, aimed at supporting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of therapeutic agents for neurological and neuromuscular disorders. This grant follows the R61/R33 phased award mechanism, where the R61 phase focuses on preparation and characterization, while the R33 phase emphasizes efficacy studies, with a critical transition contingent upon meeting specific milestones. The program encourages collaboration among various organizations, including nonprofit entities and academic institutions, to accelerate the development of promising therapies, with awards capped at $750,000 over a maximum project duration of three years. Interested applicants can find more information and application instructions at the NIH grants website, and the deadline for submissions is October 20, 2027.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Stimulating Access to Research in Residency Transition Scholar (StARRTS)" aimed at supporting career development for new investigators in biomedical, behavioral, and clinical research. This program is designed for candidates who have completed a R38 program, facilitating their transition to research independence and addressing the nation's research needs. While applications are not currently being solicited, potential applicants are encouraged to prepare meaningful collaborations and projects in anticipation of the opportunity, which is expected to open for applications in August 2025. Interested parties can reach out to Dr. David Schopfer at david.schopfer@nih.gov or by phone at 301-402-3833 for further information.
    Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Stimulating Access to Research in Residency (StARR) program, aimed at enhancing the research capabilities of resident clinicians in training. This initiative seeks to recruit and retain clinician-investigators by providing up to two years of research support, which includes funding for salary, travel, and supplementary research activities. The program is critical for fostering the development of clinician-investigators who can contribute to basic, clinical, and translational research, thereby addressing the growing need for skilled professionals in the health sector. Interested applicants must submit their proposals by January 10, 2028, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of General Medical Sciences (NIGMS), is offering funding under the Innovative Programs to Enhance Research Training (IPERT) initiative (R25) to support educational activities aimed at enhancing the biomedical research workforce. The program seeks to develop innovative courses, curriculum methods, and mentoring activities for participants at various career stages, from undergraduates to professionals, with a strong emphasis on inclusivity through a required Plan for Enhancing Diverse Perspectives (PEDP). This funding opportunity is crucial for broadening access to research training and addressing the evolving needs of the biomedical sector, with a maximum budget of $500,000 per year for a project period of up to five years. Interested applicants can find more information and guidelines at the NIH grants website and should direct inquiries to grantsinfo@nih.gov, with applications due by October 14, 2026.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Innovation Grants to Nurture Initial Translational Efforts (IGNITE) aimed at developing assays and identifying therapeutic agents for neurological and neuromuscular disorders. This funding opportunity encourages research grant applications focused on assay development and iterative screening to characterize potential therapeutics, operating under the R61/R33 phased award mechanism that requires progression based on achieving specific milestones. The initiative is crucial for advancing scientific knowledge and addressing significant health challenges, with a total estimated program funding of $750,000 and an award ceiling of $750,000. Applications are due starting January 18, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.